Glenstar Extends Wildhorse Drilling After Encouraging Rattlesnake Zone Results in Nevada

New updates have been reported about Glenstar Minerals Inc.

Glenstar Minerals Inc. has completed Phase 1 reverse circulation drilling at its Wildhorse Project in Mineral County, Nevada, expanding the program from a planned 3,500 feet to 4,300 feet after encouraging field observations. The company drilled six holes at the Rattlesnake Zone, following four earlier holes at the Coca Cola Zone, targeting what it believes to be the core of a potentially high‑grade polymetallic system.

Rattlesnake drilling tested down‑dip extensions 85 to 110 meters east of historic decline workings, with all holes intersecting strongly altered, quartz‑veined meta‑sedimentary host rocks at depths of 100 to 150 meters and, in holes RTSRC‑3 and RTSRC‑6, from surface to 25 meters. Contacts with a feldspar porphyry intrusive showed particularly intense alteration and oxide mineralization, which Glenstar’s technical team views as supportive of a significant near‑surface and deeper polymetallic resource opportunity pending assay confirmation.

Project Geologist and Exploration Manager Bob Marvin reported that drilling results indicate robust, area‑wide poly‑sulfide mineralization at Rattlesnake, and management is now awaiting assays to quantify grade, continuity, and potential resource scale. The Wildhorse Property comprises 89 mineral claims covering 1,780 acres and hosts multiple east‑dipping mineralized zones, with historical sampling showing more than 1 gram per tonne gold, 1% copper, and high antimony, plus bismuth and tungsten pointing to a focused intrusive‑related polymetallic system.

For Glenstar, Wildhorse represents a strategically important U.S.‑based critical minerals asset aligned with its focus on supplying metals essential for advanced electronics and energy technologies. While the current update is technical and non‑resource in nature, the expanded drilling and strong visual mineralization increase the project’s exploration significance and could influence future capital allocation, joint‑venture discussions, or financing once assay data and follow‑up plans are disclosed.